et140202 autologous t cell product
Liver Neoplasm
Eureka Therapeutics Inc.Cell therapyPhase 1Dormant
CC
43/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 28/ 100
- Competitive Position
- 95/ 100
Competitive context
24 Active assets in the Liver Neoplasm cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Irinotecan Tehran University of Medical Sciences | Phase 4 | BBB |
Eloxatin Shanghai Zhongshan Hospital | Phase 4 | BB |
ALBUMIN AGGREGATED Sirtex Medical | Phase 4 | BB |
CHLORHEXIDINE Changhua Christian Hospital | Phase 4 | BB |
Talaporfin Light Sciences Oncology | Phase 3 | BB |
View all 50 →
Same molecule, other indications
et140202 autologous t cell product is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →